Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis
Authors
Keywords
-
Journal
Journal of Crohns & Colitis
Volume 8, Issue 12, Pages 1632-1641
Publisher
Oxford University Press (OUP)
Online
2014-07-25
DOI
10.1016/j.crohns.2014.07.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial
- (2016) Remo Panaccione et al. CANADIAN JOURNAL OF GASTROENTEROLOGY
- Tu1158 Evaluating Adalimumab Drug and Antibody Levels As Predictors of Clinical and Laboratory Response in Crohn's Disease Patients
- (2015) Yoav Mazor et al. GASTROENTEROLOGY
- Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
- (2014) Gerd-Rűdiger Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)
- (2014) Tsutomu Takeuchi et al. Modern Rheumatology
- Infectious and Malignant Complications of TNF Inhibitor Therapy in IBD
- (2013) Laura E Targownik et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
- (2013) Niels Vande Casteele et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2013) Alessandro Liberati ANNALS OF INTERNAL MEDICINE
- Optimizing anti-TNF treatments in inflammatory bowel disease
- (2013) Shomron Ben-Horin et al. AUTOIMMUNITY REVIEWS
- Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study
- (2013) S.K. Mahil et al. BRITISH JOURNAL OF DERMATOLOGY
- Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti–Tumor Necrosis Factor-α Agents
- (2013) Christine Kestens et al. Clinical Gastroenterology and Hepatology
- Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease
- (2013) Mark T. Osterman et al. GASTROENTEROLOGY
- The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
- (2013) Bella Ungar et al. GUT
- Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease
- (2013) Yi-Lin Chiu et al. INFLAMMATORY BOWEL DISEASES
- The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients
- (2013) D.R. Wong et al. Journal of Crohns & Colitis
- Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay
- (2013) Shui-Long Wang et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?
- (2012) C. Reenaers et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
- (2012) Shomron Ben–Horin et al. Clinical Gastroenterology and Hepatology
- Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
- (2012) Tomoyuki Imagawa et al. CLINICAL RHEUMATOLOGY
- Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
- (2012) Paul Rutgeerts et al. GASTROENTEROLOGY
- P291 Infliximab versus adalimumab in Crohn's disease patients in daily clinical practice. A prospective single center experience
- (2012) F. Bossa et al. Journal of Crohns & Colitis
- Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients
- (2012) Filip Baert et al. Journal of Crohns & Colitis
- Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn’s disease
- (2011) M. A. Kamm et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients
- (2011) E. Bultman et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: loss of response to anti-TNF treatments in Crohn’s disease
- (2011) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease
- (2011) L. S. Kiss et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience
- (2011) José Ignacio Fortea-Ormaechea et al. Gastroenterologia y Hepatologia
- Predictors of adalimumab dose escalation in patients with crohnʼs disease at a tertiary referral center
- (2011) Russell D. Cohen et al. INFLAMMATORY BOWEL DISEASES
- Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CARE
- (2011) Robert Löfberg et al. INFLAMMATORY BOWEL DISEASES
- Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience
- (2011) Michael B. Sprakes et al. Journal of Crohns & Colitis
- Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy
- (2010) H. Sokol et al. GUT
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
- Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
- (2008) Gert Van Assche et al. GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now